stockportfolio.pro
Becton, Dickinson and Company (BDX)
Healthcare · Medical Instruments & Supplies · NYSE
Becton, Dickinson and Company revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.48B | $12.09B | $15.98B | $17.29B | $16.07B | $19.13B | $18.87B | $19.37B | $20.25B | $21.84B |
| Gross profit | $5.99B | $5.94B | $7.27B | $8.29B | $7.58B | $8.63B | $8.48B | $8.17B | $9.19B | $9.93B |
| Net income | $976.00M | $1.10B | $311.00M | $1.23B | $874.00M | $2.09B | $1.69B | $1.42B | $1.73B | $1.68B |
| Net margin | 7.8% | 9.1% | 1.9% | 7.1% | 5.4% | 10.9% | 9.0% | 7.4% | 8.5% | 7.7% |
Source: Becton, Dickinson and Company SEC filings (10-K). 19 years of history available in the interactive view.
What growth is priced into BDX stock?
At today's market cap of $41.89B, Becton, Dickinson and Company is priced for free-cash-flow growth of about 4.4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $2.67B from the FY ending 2025-09-30). For comparison, free cash flow actually grew -0.7%/yr over the last five fiscal years and revenue 6.3%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of Becton, Dickinson and Company financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BDX in your portfolio →
Becton, Dickinson and Company financial history by metric
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Becton, Dickinson and Company — frequently asked questions
What is Becton, Dickinson and Company's revenue?
Becton, Dickinson and Company (BDX) reported revenue of $21.84B for fiscal year 2025, up 7.9% from the prior year, according to its SEC filings.
Is Becton, Dickinson and Company profitable?
Yes. BDX earned net income of $1.68B in fiscal 2025, a net margin of 7.7%.
What is BDX's P/E ratio?
Becton, Dickinson and Company trades at a price-to-earnings ratio of about 26.5 based on the latest data in our nightly-refreshed cache.
How fast is Becton, Dickinson and Company growing?
BDX's revenue grew at roughly 6.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Becton, Dickinson and Company have?
As of fiscal year 2025, BDX carried roughly $19.18B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Becton, Dickinson and Company's gross margin?
BDX's gross margin was 45.4% in fiscal 2025 — gross profit of $9.93B on revenue of $21.84B.
What is Becton, Dickinson and Company's market cap?
Becton, Dickinson and Company (BDX) has a market capitalization of about $41.89B, based on the latest data in our nightly-refreshed cache.
When does Becton, Dickinson and Company's fiscal year end?
BDX's fiscal year ends in September. Its most recent annual filing covers the fiscal year ending 2025-09-30.
What growth is priced into BDX stock?
At today's market cap of $41.89B, Becton, Dickinson and Company is priced for free-cash-flow growth of about 4.4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $2.67B from the FY ending 2025-09-30). For comparison, free cash flow actually grew -0.7%/yr over the last five fiscal years and revenue 6.3%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Becton, Dickinson and Company's official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.